Twist Bioscience (NASDAQ:TWST) SVP Paula Green Sells 9,724 Shares

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 9,724 shares of Twist Bioscience stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total transaction of $313,015.56. Following the completion of the transaction, the senior vice president directly owned 114,678 shares of the company’s stock, valued at $3,691,484.82. The trade was a 7.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Monday, September 22nd, Paula Green sold 295 shares of Twist Bioscience stock. The shares were sold at an average price of $27.56, for a total transaction of $8,130.20.
• On Monday, September 8th, Paula Green sold 892 shares of Twist Bioscience stock. The shares were sold at an average price of $25.76, for a total transaction of $22,977.92.

Twist Bioscience Stock Up 5.4%

TWST opened at $32.79 on Thursday. Twist Bioscience Corporation has a fifty-two week low of $24.07 and a fifty-two week high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The company has a fifty day moving average of $27.72 and a two-hundred day moving average of $32.84. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -22.61 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to analysts’ expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Cowen reissued a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI cut their target price on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Barclays lowered their price target on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a research report on Thursday, October 2nd. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after purchasing an additional 1,588,587 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Twist Bioscience by 18.5% in the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company’s stock valued at $251,000 after purchasing an additional 1,006 shares during the last quarter. Strs Ohio acquired a new position in Twist Bioscience in the 1st quarter valued at about $711,000. Wealth Enhancement Advisory Services LLC acquired a new position in Twist Bioscience in the 1st quarter valued at about $396,000. Finally, GAMMA Investing LLC boosted its holdings in Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after purchasing an additional 303 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.